Evidence map›Paper›PMID 35857753›Full record

ArticlePloS one2022

Initial experience with AI Pathway Companion: Evaluation of dashboard-enhanced clinical decision making in prostate cancer screening.

Maurice Henkel, Tobias Horn, Francois Leboutte, Pawel Trotsenko, Sarah Gina Dugas, Sarah Ursula Sutter, Georg Ficht, Christian Engesser, Marc Matthias, Aurelien Stalder and 5 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
7.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 3 countries.

Maurice HenkelResearch & Analytic Services University Hospital Basel, Basel, Switzerland.ORCID 0000-0002-7560-0938
Tobias HornUniversity Basel, Basel, Switzerland.
Francois LeboutteUniversity Basel, Basel, Switzerland.
Pawel TrotsenkoUniversity Basel, Basel, Switzerland.
Sarah Gina DugasUniversity Basel, Basel, Switzerland.
Sarah Ursula SutterUniversity Basel, Basel, Switzerland.
Georg FichtUniversity Basel, Basel, Switzerland.
Christian EngesserUniversity Basel, Basel, Switzerland.
Marc MatthiasUniversity Basel, Basel, Switzerland.
Aurelien StalderSiemens Healthineers GmbH, Erlangen, Germany.
Jan EbbingUniversity Basel, Basel, Switzerland.
Philip CornfordDepartment of Urology, Liverpool University Hospitals NHS Trust, Liverpool, United Kingdom.
Helge SeifertUniversity Basel, Basel, Switzerland.
Bram StieltjesResearch & Analytic Services University Hospital Basel, Basel, Switzerland.
Christian WetterauerUniversity Basel, Basel, Switzerland.
University Hospital of Basel · CHDanube Private University · ATSiemens Healthineers (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeRising complexity of patients and the consideration of heterogeneous information from various IT systems challenge the decision-making process of urological oncologists. Siemens AI Pathway Companion is a decision support tool that provides physicians with comprehensive patient information from various systems. In the present study, we examined the impact of providing organized patient information in comprehensive dashboards on information quality, effectiveness, and satisfaction of physicians in the clinical decision-making process.

methodsTen urologists in our department performed the entire diagnostic workup to treatment decision for 10 patients in the prostate cancer screening setting. Expenditure of time, information quality, and user satisfaction during the decision-making process with AI Pathway Companion were recorded and compared to the current workflow.

resultsA significant reduction in the physician's expenditure of time for the decision-making process by -59.9% (p < 0,001) was found using the software. System usage showed a high positive effect on evaluated information quality parameters completeness (Cohen's d of 2.36), format (6.15), understandability (2.64), as well as user satisfaction (4.94).

conclusionThe software demonstrated that comprehensive organization of information improves physician's effectiveness and satisfaction in the clinical decision-making process. Further development is needed to map more complex patient pathways, such as the follow-up treatment of prostate cancer.

Indexed as

Early Detection of CancerProstatic NeoplasmsArtificial IntelligenceClinical Decision-MakingDecision MakingHumansMaleProstate-Specific AntigenProstate-Specific Antigen

Identifiers

PMID35857753
PMCPMC9299327
OpenAlexW4286209811

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.